Observed Signal · Oct 26, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 3/5 · Sentiment: Positive
Leeds AI Startup adsilico Raises £10M for Virtual Medical Device Testing
adsilico, a University of Leeds spinout, has raised £10 million in a Series A funding round. The investment was led by PXN Ventures, with participation from existing investors Northern Gritstone and Parkwalk. Founded in 2024, adsilico develops AI-powered simulation technology that creates virtual patient populations to assess medical device performance. Their platform, Virtual Chimera, uses generative AI to create virtual hearts and blood vessels from anonymized clinical scans, combined with physics-based simulations. This allows medical device manufacturers to evaluate device performance across diverse patient demographics, aiding in development decisions such as device sizing, risk identification, and clinical trial strategy. The new funds will support expansion into neurovascular devices and increase the workforce. adsilico has already completed projects with heart valve and neurovascular device manufacturers.
The funding highlights the growing application of generative AI in healthcare, specifically for medical device testing, indicating a trend toward AI-driven simulation in regulated industries.
Track Real-Time HealthTech Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- adsilico raised £10 million in a Series A funding round led by PXN Ventures.
- Existing investors Northern Gritstone and Parkwalk participated in the round.
- adsilico was founded in 2024 by Sheena Macpherson, Dr Nishant Ravikumar, and Dr Zeike Taylor.
- The company's platform, Virtual Chimera, uses generative AI to create virtual hearts and blood vessels from anonymized clinical scans.
- adsilico plans to expand into neurovascular devices and increase its workforce.
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
XRlabs Raises €7.48M for AI Surgical Intelligence
London-based XRlabs, a Surgical Intelligence company founded by neurosurgeon Dr. Ali Haddad, has raised €7.48 million ($8.4 million) in Seed funding. The round was led by Playground Global (Palo Alto), with participation from London-based HealthTech investor Eka Ventures. The company develops modular, device-agnostic software that uses computer vision and deep learning to transform live surgical video, navigation telemetry, and pre-operative imaging into a real-time, anatomy-aware view. Its platform has been deployed in over 100 surgical cases across three continents. The funding will support engineering and clinical team expansion, regulatory advancement in the UK, EU, and US, and the extension of clinical evidence. XRlabs also announced Omar Ishrak, former CEO of Medtronic, as Chair of its Board. The company has been awarded compute allocation on the UK AI Research Resource (AIRR).
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
Physicl raises $10M seed to boost robot training simulations
Physicl, a startup founded by Alex de Vigan, has raised $10 million in seed funding led by Inovia Capital. The company aims to bridge the sim-to-real gap in robotics by repurposing a pipeline originally built for e-commerce product renderings. This pipeline transforms unstructured real-world data into high-fidelity 3D physical representations, which can be used to generate synthetic training data for physical AI models. Physicl is launching a product called Studio, featuring 10,000 3D environments and 100,000 assets, to help post-train models on edge cases. The startup already has an early customer, SpAItial, a world model builder that used Physicl's data to improve its Echo-3 product. Physicl sees itself as providing ongoing synthetic data generation tooling, with potential for agentic workflows that auto-generate data on demand. The company enters a crowded field of startups providing data and tools for robot training, but focuses on high-fidelity, physics-accurate simulations.
Receive all future signals for HealthTech in your executive briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.